Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...

Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over allegations their premature infant formula can cause a serious gut condition.

Reckitt Benckiser is continuing to assess options for its nutrition operations housing the Mead Johnson infant-formula business. After describing nutrition as “non-core” in July as part of a ...

The stable outlook reflects Moody’s base case expectations that Reckitt’s gross debt/EBITDA leverage will stay at or below 2.5x, and that the company’s competitive position will continue to support ...

Reckitt Benckiser is moving forward with the sale of its nutrition operations housing the Mead Johnson infant-formula ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new trial against the companies.

“There may also be disappointment that Reckitt didn’t have anything more definitive to say about an exit from its Mead Johnson infant formula arm. The $18 billion capture of this business in ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary, Mead Johnson, not responsible for a baby developing necrotizing enterocolitis, or NEC, from their cow ...

Core Reckitt, Essential Home, and Mead Johnson Nutrition. Like many businesses, the group, which makes everything from Dettol to Nurofen, is looking to streamline its operations and ramp up return ...